Beta-Blockers Improve Survival in HFrEF
Beta-blockers are the correct answer among the options listed, as they have been definitively proven to reduce mortality in patients with heart failure with reduced ejection fraction. 1, 2
Evidence-Based Mortality Reduction
The guidelines are unequivocal: beta-blockers carry a Class I, Level A recommendation for reducing both hospitalization and death in symptomatic HFrEF patients. 1, 2 Specifically, only three beta-blockers have demonstrated mortality benefit in landmark trials:
- Carvedilol (non-selective)
- Metoprolol succinate (sustained-release, beta-1 selective)
- Bisoprolol (beta-1 selective)
These agents reduce all-cause mortality by at least 20% and importantly also reduce sudden cardiac death—a benefit that cannot be delayed even in clinically stable patients. 3
Why the Other Options Are Wrong
Nondihydropyridine calcium channel blockers (diltiazem, verapamil): These are explicitly contraindicated in HFrEF with a Class III recommendation, as they increase the risk of heart failure worsening and hospitalization. 1
Loop diuretics: While essential for symptom management and volume control (Class I recommendation), diuretics have never been shown to improve survival in HFrEF. 1, 2 They improve symptoms and exercise capacity but do not modify disease progression or mortality.
Digoxin: Similarly, digoxin may help with symptom control but has not demonstrated mortality benefit in HFrEF trials.
Complete Mortality-Reducing Regimen
For context, the current standard of care for this 70-year-old patient should include four foundational medication classes that all reduce mortality 4, 5:
- ACE inhibitor or ARB (or preferably ARNI/sacubitril-valsartan)
- Beta-blocker (one of the three proven agents)
- Mineralocorticoid receptor antagonist (spironolactone/eplerenone)
- SGLT2 inhibitor (dapagliflozin/empagliflozin)
Recent network meta-analyses demonstrate that quadruple therapy with ARNI, beta-blocker, MRA, and SGLT2i provides the greatest mortality reduction (HR 0.39,95% CI 0.32-0.49 vs. placebo), translating to approximately 5 additional life-years for a 70-year-old patient. 5, 6
Critical Implementation Point
Beta-blockers should be initiated as soon as HFrEF is diagnosed, even when symptoms are mild or controlled with other therapies. 7 The survival benefit is substantial and applies across subgroups including elderly patients (≥70 years), octogenarians, women, and those with or without coronary artery disease. 8, 9 The mortality benefit persists even in very elderly patients (≥80 years). 8
The common clinical pitfall is delaying beta-blocker initiation due to concerns about hypotension or bradycardia—these agents should be started at low doses and uptitrated systematically to target doses proven in clinical trials, as subtarget dosing has not been shown to provide equivalent mortality benefit. 3